|
End-of-day quote
Mexican S.E.
25/09/2026
|
5-day change | 1st Jan Change | ||
| 2,572.00 MXN | +5.24% |
|
+5.24% | +2.88% |
| 05:54pm | Merck's experimental skin disease drug succeeds in mid-stage study | RE |
| 05:50pm | Major drugmakers turn to China for licensing deals | RE |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
Data source:
Novartis AG(NOVN)
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Data source:
Novartis AG(NOVN)
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
Data source:
Novartis AG(NOVN)
EBIT
Dividend / Share (DPS)
Data source:
Novartis AG(NOVN)
Cash or Net Debt
- Stock Market
- Stocks
- NOVN Stock
- NVS N Stock
- Consensus Novartis AG
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
